<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="401">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493855</url>
  </required_header>
  <id_info>
    <org_study_id>M14-242</org_study_id>
    <secondary_id>2014-001478-32</secondary_id>
    <nct_id>NCT02493855</nct_id>
  </id_info>
  <brief_title>Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults</brief_title>
  <official_title>An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of ombitasvir/ABT-450/ritonavir and dasabuvir with low dose ribavirin (RBV),
      full dose RBV or RBV add on in treatment naive subjects with chronic Hepatitis C Virus
      (HCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to evaluate the effect of RBV on second phase plasma HCV ribonucleic acid (RNA)
      decline in subjects who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose
      RBV compared to ombitasvir/ABT-450/ritonavir with low dose RBV or without RBV in
      treatment-naive HCV genotype (GT) 1a-infected adult subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Slope of the second phase decline in plasma HCV RNA levels during treatment</measure>
    <time_frame>From Week 0 to Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of RBV on second phase plasma HCV ribonucleic acid (RNA) decline in subjects who receive the 3-direct-acting antiviral agent (DAA) regimen of ombitasvir/ABT-450/r and dasabuvir with full dose RBV compared to the 3-DAA regimen with low dose RBV or without RBV in treatment-naive HCV genotype (GT) 1a-infected adult subjects.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C (HCV)</condition>
  <condition>Hepatitis C Genotype 1a</condition>
  <arm_group>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir 12 weeks + RBV last 10 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r once daily (QD) + dasabuvir twice daily (BID) for 12 weeks + weight-based RBV (1000 mg or 1200 mg split BID) for the last 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV weight-based 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r once daily (QD) + dasabuvir twice daily (BID) + weight-based RBV (1000 mg or 1200 mg split BID) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV low dose 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r once daily (QD) + dasabuvir twice daily (BID) + RBV 600 mg QD for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/ABT-450/ritonavir</intervention_name>
    <description>ombitasvir/ABT-450/ritonavir tablets</description>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir 12 weeks + RBV last 10 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV weight-based 12 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV low dose 12 weeks</arm_group_label>
    <other_name>ABT-267/ABT-450/ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <description>dasabuvir tablets</description>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir 12 weeks + RBV last 10 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV weight-based 12 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV low dose 12 weeks</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>ribavirin tablets</description>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir 12 weeks + RBV last 10 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV weight-based 12 weeks</arm_group_label>
    <arm_group_label>Ombitasvir/ABT-450/r + dasabuvir + RBV low dose 12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Screening laboratory result indicating HCV genotype 1 (GT1) a infection.

          2. Chronic HCV infection.

          3. Subjects must be non-cirrhotic.

          4. Subjects must be able to understand and adhere to the study visit schedule and all
             protocol requirements as well as voluntarily sign and date an institutional review
             board (IRB) approved informed consent.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab) positive immunoassay.

          3. Clinically significant abnormalities or co-morbidities, other than HCV infection,
             that make the subject unsuitable for this study or treatment.

          4. Current enrollment in another interventional clinical study. Previous use of any HCV
             treatments including pegylated interferon (pegIFN), ribavirin, or any direct acting
             antiviral agent, either investigational or approved, for HCV including protease
             inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or NS5A inhibitors.

          5. History or solid organ transplant.

          6. Screening laboratory analysis that shows abnormal results.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Dumas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christal Marincic, BS</last_name>
    <phone>847-936-1151</phone>
    <email>christal.marincic@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manohara Halasiddappa, BS</last_name>
    <phone>847-935-0458</phone>
    <email>manohara.halasiddappa@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131934</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 131934, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132539</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132539, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>July 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 1a</keyword>
  <keyword>Interferon free</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Treatment naive</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
